Astellas Pharma Closing Two N.Y. Facilities By June 2011
“Astellas Pharma Inc. is planning to close two facilities in New York that had been operated by OSI Pharmaceuticals Inc., which the Japanese drug maker bought for $4 billion in June. An Astella spokeswoman said that OSI’s Ardsley and Melville facilities will close by June 2011, affecting about 150 workers at those sites…more“
AstraZeneca Hopeful for Positive FDA Call on Blood-Thinner but Doubts Linger
“An FDA advisory committee’s strong vote in favor of AstraZeneca’s (AZN) blood-thinner Brilinta was tempered by long-held concerns over the failure of the drug’s pivotal trial to show a survival benefit in the US population when compared to Plavix (Event – Brilinta has questions to answer, July 21, 2010). With adcom members raising concerns over [...]
Sanofi fights FDA approval of generic Lovenox
“The FDA has approved the first generic version of the blockbuster low molecular weight heparin Lovenox (enoxaparin sodium), much to originator sanofi-aventis’s displeasure. Sanofi has expressed concerns about the generic’s safety and, according to a report from Reuters, has even asked a court to block the approval, claiming that the FDA’s decision was “arbitrary and [...]
AstraZeneca settles kickback marketing case
“Pharmaceutical giant AstraZeneca will pay $520 million to settle allegations that the company illegally marketed an antipsychotic drug and paid kickbacks to physicians, the Justice Department announced Tuesday…more.”
————–
Editor’s Comments: They used to be a great company when they were Astra. But it seems like they have become another greedy corporate entity. Zeneca changed their direction.
New Guidance: Dissolution Test General Chapter
Guidance for Industry
_________________________________
Q4B Evaluation and Recommendation
of Pharmacopoeial Texts for Use in the ICH Regions
Annex 7
Dissolution Test General Chapter
Abbott To Acquire Facet Biotech
Abbott has agreed to acquire Facet Biotech for $27 per share in cash for a net transaction value of approximately $450m to enhance its early- and mid-stage pharmaceutical pipeline.
keep looking »
